Insiders · KZIA

David Cain

Director, CMC at Kazia Therapeutics Ltd (KZIA) since March 2026

David Cain has filed 2 insider reports with the SEC since April 2026, as director and CMC at Kazia Therapeutics Ltd (KZIA). The latest filing, on July 8, 2026, reports grant or award at Kazia Therapeutics Ltd (KZIA).

Filings
2
Companies
1
Bought on market
None
Sold on market
None

Companies where David Cain is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Kazia Therapeutics Ltd logo
KZIA
Kazia Therapeutics Ltd
Director, CMCsince March 2026$4.92Jul 8, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare David Cain with

Other insiders at the same companies

Questions about David Cain

What is David Cain's role at Kazia Therapeutics Ltd?
David Cain reports to the SEC as director and CMC at Kazia Therapeutics Ltd (KZIA), according to the latest filing on July 8, 2026.
Has David Cain bought or sold stock recently?
No open-market purchases or sales by David Cain are on file. The filings report grant or award.
How do I get alerts when David Cain files?
Follow David Cain on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by David Cain (SEC CIK 0002125950). Totals count each trade once, skipping amendments whose original is on file, from Apr 1, 2026 on. View on SEC EDGAR · Get this as JSON